Korro Bio (KRRO) filed a registration statement Monday with the US Securities and Exchange Commission covering the potential sale of up to $400 million of its securities from time to time.
The filing covers a base prospectus for up to $400 million of debt securities, common stock, preferred stock, units, and warrants in one or more offerings, including an "at the market offering" of up to $100 million of common shares under a sales agreement with TD Securities.
Proceeds will be used for general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.